PT-141 (Bremelanotide) 10mg

P-41 (bremelanotide; PT-141) is a cyclic heptapeptide melanocortin receptor agonist derived from MT-2, with preferential agonism of MC3R and MC4R — the CNS receptors governing sexual arousal via neurogenic pathways. FDA-approved in 2019 as Vyleesi® for hypoactive sexual desire disorder in premenopausal women — the first non-hormonal drug approved for this indication.

• Central nervous system mechanism — activates MC3R and MC4R in the hypothalamus via neurogenic pathways, distinct from vascular PDE5 inhibitors.
• FDA-approved compound — approved 2019 as Vyleesi® for HSDD — the only non-hormonal option for female sexual desire disorder.
• Erectile function research — Phase 2 data: 34% of male subjects reported significantly improved erectile function vs. 9% placebo.
• Dual-gender relevance — consistent improvements in both male and female research models.
• Selective vs. MT-2 — refined selectivity reduces melanogenesis and appetite signalling while preserving sexual function receptor activation.

⚠️ For research use only. Not for human or animal consumption. Store at −20°C. Reconstitute with Bacteriostatic Water.